Result:Good· Market: Down#Margin expansion#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 42.77 | 19.6% | 22.2% |
| Total Income | 43.38 | 18.8% | 23.0% |
| Expenditure | 37.09 | 16.7% | 11.4% |
| PBT | 6.29 | 33.0% | 218.5% |
| Net Profit | 4.60 | 29.1% | 257.4% |
| OPM | 16.28% | 1.53pp | 7.67pp |
| NPM | 10.60% | 0.85pp | 6.95pp |
| EPS | 2.55 | 37.8% | 244.6% |
Pharma: healthy 22% revenue growth with genuine margin expansion (OPM 8.6%→16.3%) drove profit up, but the 257% PAT growth is flattered by a thin, depressed year-ago base, capping it below very_good.
Informational and educational content only. Not investment advice.